Up next

Autoplay

Pharmacology of Selumetinib for treatment of Neurofibromatosis-1 (New Drug 2020)

2 Views • 07/02/23
Share
Embed
administrator
administrator
Subscribers
0

Pharmacology of Selumetinib for treatment of Neurofibromatosis-1 (New Drug 2020)

MOA – MEK 1/2 or Mitogen Activated Protein Kinase 1/2 inhibitor

Use: Neurofibromatosis-1 which is symptomatic/inoperable

Effect: Selumetinib decreases size and number of neurofibromas.

Route – Oral

Dose – 25 mg/m2 on empty stomach

Side-effects:
GIT – N/V, Diarrhoea
Rhabdomyolysis
Ocular toxicity
Cardiomyopathy

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay